title: Natural interferon alfa for treatment of condylomata acuminata.
abstract: The activity of natural (leukocyte) interferon alfa in the treatment of condylomata acuminata was assessed in a randomized, double-blind, placebo-controlled, multicenter trial. Interferon alfa (Alferon N Injection) or placebo was injected into lesions twice weekly for up to eight weeks. Eighty-six patients were given interferon alfa, and 72 were given placebo. Eighty-six percent of interferon alfa-treated patients and 89% of placebo-treated patients had received previous therapy for condylomata acuminata. Side effects, usually flulike symptoms, occurred briefly after the injections; if present, they disappeared before the end of the third week of therapy. Treatment completely eliminated warts in 62% of interferon alfa-treated patients compared with only 21% of placebo-treated patients. Natural interferon alfa given intralesionally is an effective and safe treatment even in patients with recurrent or recalcitrant genital warts.
authors.affiliation: Department of Dermatology, New York University Medical Center 10016.
authors.forename: A E
authors.initials: AE
authors.lastname: Friedman-Kien
authors.forename: L J
authors.initials: LJ
authors.lastname: Eron
authors.forename: M
authors.initials: M
authors.lastname: Conant
authors.forename: W
authors.initials: W
authors.lastname: Growdon
authors.forename: H
authors.initials: H
authors.lastname: Badiak
authors.forename: P W
authors.initials: PW
authors.lastname: Bradstreet
authors.forename: D
authors.initials: D
authors.lastname: Fedorczyk
authors.forename: J R
authors.initials: JR
authors.lastname: Trout
authors.forename: T F
authors.initials: TF
authors.lastname: Plasse
mesh_terms: D000328:Adult; D003218:Condylomata Acuminata / Q000628:therapy*; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D005334:Fever / Q000209:etiology; D005833:Genital Neoplasms, Female / Q000628:therapy*; D005834:Genital Neoplasms, Male / Q000628:therapy*; D006801:Humans; D007251:Influenza, Human / Q000209:etiology; D007370:Interferon Type I / Q000009:adverse effects / Q000627:therapeutic use*; D007958:Leukocyte Count; D008297:Male; D011897:Random Allocation
chemical_list: D007370:Interferon Type I